FMT

This week on #Breakpoints, @anniejayTX and @DrPaulGastro talk with @RachelBPharmD about the microbiome 🦠and the role of microbiota-based live biotherapeutic products in C. difficile management. 💩Listen now! https://t.co/XTxayHN3gy pic.twitter.com/7dwmBMXS5p— SIDP (@SIDPharm) August 26, 2022

Using strain-level microbiota profiling in patients treated with fecal microbiota transplantation (FMT), Podlesny et al. identify a mechanistic framework for post-FMT microbiome assembly that aligns with ecological theory. Donor strain engraftment is dependent on microbiome and clinical parameters, including antibiotic treatment and bowel lavage, independently of the treated disease.

Patients with recurrent Clostridium difficile (C. diff) should be offered a faecal microbiota transplant (FMT), NICE has recommended.

Hundreds of people with recurrent bacterial infections could be treated with gut bacteria taken from a healthy donor’s poo. NICE has recommended a faecal microbiota transplant.

Want to know the one reason why one of the first #FMT (💩) performing physicians in Germany switched from jejunal to colonic application?Check out the new ENDO Podcast (in 🇩🇪)#GiTwitter, #endoscopy@Endo_OC, @DGVSJuGa, @MarcusHollenba1, @WatchMeFail1 https://t.co/6hNsOl95AJ— Alexander Hann (@alexsworking) August 30, 2022

About the Microbiome THE MICROBIOME The human microbiome provides metabolic and synthetic functions essential to the human health, including regulating the immune system and aiding in digestion. It also provides protection against colonization and invasion by potential microbial pathogens. Through a complex network of interacting microbes, the microbiome directly or indirectly affects

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterised by deficits in social behaviour, increased repetitive behaviour, anxiety…

The enormous and diverse population of microorganisms residing in the digestive tracts of humans and animals influence the development, regulation, and function of the immune system. Recently, the understanding of the association between autoimmune diseases and gut microbiota has been improved due t …

Clostridioides difficile (C. difficile) is a gram-positive, anaerobic, spore-forming bacterium that produces toxins A and B, disrupting the intestinal brush border and resulting in severe diarrh...

I'm done with the "walks for a cure" for real, it's been 30 years, and we still treat diseases like #crohns with immunosuppression. Yet, promising therapies like dietary interventions, #bioelectronicmedicine #FMT are stuck on the hamster wheel of "needs more research." (10/15) pic.twitter.com/saqrOBXrVG— Natalie RDH BHA (@DHadvocate1) August 24, 2022

Includes media briefing video from the ACS.

The FDA has determined the need for additional safety protections after recent studies have documented the presence of monkeypox virus DNA in rectal swabs and/or stool samples from infected individuals.

Background Autism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children. Results MTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. Improvements persisted 8 weeks after treatment. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks). Conclusions This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact. Trial registration This trial was registered on the ClinicalTrials.gov, with the registration number NCT02504554

This is a good study but protocol proposed isn't practical and donors recruited (rural) are not generalisable to IBD prevalent countries. Future of FMT in IBD is less clear because unlike a lab manufactored drug FMT is very different.https://t.co/Y4To4tIqSA— Nabil Quraishi (@NabilQuraishi) August 22, 2022

Mucosal microbiota differ significantly from fecal microbiota and may play a different role in the pathophysiology of irritable bowel syndrome (IBS). The aims of this study were to determine if the composition of mucosal microbiota differed between IBS, or IBS bowel habit (BH) subtypes, and healthy controls (HCs). Sigmoid colon mucosal biopsies were obtained from 97 Rome-positive patients with IBS (28% IBS-constipation, 38% IBS-diarrhea, 24% IBS-mixed, and 10% IBS-unsubtyped) and 54 HCs, from which DNA was extracted. 16S rRNA gene sequencing and microbial composition analysis were performed. Group differences in α and β diversity and taxonomic level differences were determined using linear regression while controlling for confounding variables. IBS BH subtype was associated with microbial α diversity (P = 0.0003) with significant differences seen in the mucosal microbiota of IBS-constipation versus IBS-diarrhea (P = 0.046). There were no significant differences in α or β diversity in the mucosal microbiota of IBS versus HCs (P = 0.29 and 0.93, respectively), but metagenomic profiling suggested functional differences. The relative abundance of Prevotella_9 copri within IBS was significantly correlated with increased abdominal pain (r = 0.36, P = 0.0003), which has not been previously reported in IBS. Significant differences in the mucosal microbiota were present within IBS BH subtypes but not between IBS and HCs, supporting the possibility of IBS BH subtype-specific pathogenesis. Increased Prevotella copri may contribute to symptoms in patients with IBS. NEW & NOTEWORTHY Gut mucosal microbiota differs significantly from fecal microbiota in irritable bowel syndrome (IBS) and may play a different role in its pathophysiology. Investigation of colonic mucosal microbiota in the largest cohort of patients with IBS and healthy controls accounting for confounding variables, including diet demonstrated significant differences in mucosal microbiota between IBS bowel habit subtypes but not between IBS and healthy controls. In addition, the study reported gut microbiota is associated with abdominal pain in patients with IBS.

FDA is providing information to health care providers and patients about the potential risk of transmission of monkeypox virus through FMT products

Abstract The composition and diversity of the gut microbiota appear closely linked to health and disease, and are thought to be diminished by modern

We need microbiomeologists. There are many out there with specific gut directed expertise like @h_sokol @HoldGeorgina @gianluca1aniro @NabilQuraishi @Siew_C_Ng .We will see a refinement in #FMT in my opinion but we aren’t too far off— Jonathan Segal (@Jonathansegal85) August 21, 2022

Objective Faecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% efficacy compared with a second donor (36% efficacy). We characterised differences in the gut microbiota of these two donors with the aim of improving FMT donor selection. Design Faecal samples from the two donors were collected over a period of 44 (donor 1) or 70 (donor 2) weeks. The microbiome and metabolome were profiled using shotgun metagenomics and untargeted metabolomics Results Gut microbiome long-term stability was highly evident in the effective donor. Donor microbiota species evenness was a robust feature associated with clinical efficacy across two clinical trials of FMT in UC, leading to increased donor species engraftment in patients. Alpha diversity and beta diversity of donor gut microbiotas significantly differed. 90 bacterial species and one archaeon were differentially abundant between donors, 44 of which were 0.1% in relative abundance. 17/44 species were enriched in the effective donor, 11 of which (64.7%) were assembled into high-quality genomes that were prevalent (≥75% samples) in that donor, and six showed evidence of engraftment in patients. Taxonomic differences between donors translated to substantial microbial functional differences that were validated using metabolomics. Conclusion Donor microbiota stability and species evenness were identified as novel metrics that were associated with therapeutic efficacy in UC, beyond individual microbial species or metabolites. These metrics may represent community resilience that translates to better engraftment in the host. Trial registration number ACTRN12619000611123. Data are available in a public, open access repository. The raw shotgun metagenomics reads, and the associated metagenomic-assembled genomes were submitted to the European Nucleotide Archive (ENA) under the accession PRJEB50699. 16S rRNA gene amplicon reads are publicly available in ENA under the accession PRJEB48134.

At Novel Biome, we offer a choice of FMT delivery methods tailored to the needs and preferences of each patient. Our oral FMT products are are colourless, tasteless, and odourless. To learn more, check out our website, https://t.co/q4eRvak9qL#FMT #microbiome #asd #autism pic.twitter.com/BtwTCJPsSE— Novel Biome (@NovelBiome) August 19, 2022

Cordlife and AMILI are working together to store human poop for treating diseases

Invest in ME Investing in Research into ME

Fecal microbiota transplantation (FMT) consists of infusion of feces from a donor to a recipient patient in order to restore the resident microbial population. FMT has shown to be a valid clinical option for Clostridioides difficile infections (CDI). However, this approach shows several criti …

After fecal microbiota transplantation (FMT) to treat Clostridioides difficile infection (CDI), cognitive improvement is noticeable, suggesting an essential association between the gut microbiome and neural function. Although the gut microbiome has been associated with cognitive function, it …

Safety is our #1 priority, that's why our initial donor screening goes above and beyond any published standards, and we use 120 different blood and stool screening criteria, in addition to our state-of-the-art laboratory!#FMT #guthealth #asd #autism pic.twitter.com/ACSGN0dtYo— Novel Biome (@NovelBiome) August 17, 2022

AbstractBackground. Fecal microbiota transplantation (FMT) has been investigated as a treatment option for patients with inflammatory bowel disease with controv

#metagenomics @PhaseGenomics: 'Tomorrow at #ISME18, @sciberius will be presenting recent research conducted w/ Dr. Alex Khoruts & @GroveJonas on the use of proximity ligation in #fmt studies. Learn how to supercharge co… pic.twitter.com/ivnCLyP4Hx, see more https://t.co/C9fY5S13cb— MarineBio3 (@MarineGenomics) August 15, 2022